Cytovant is a biopharmaceutical company dedicated to developing novel and innovative cellular therapeutics in Asia
Our mission is to become Asia’s premier cell therapy company by rapidly discovering, developing, and commercializing new medicines tailored to Asian patients
TCR-T therapies utilize a patient’s own immune system to target tumor cells. In preparation for the therapy, a patient’s T cells are modified to express tumor-specific receptors that are then able to activate and mount an anti-tumor response. Through ex-vivo modification of a patient’s T cells, TCR-T therapy can overcome natural T cell tolerance toward cancer cells and tumor-induced immunosuppression. Unlike CAR-T therapy, TCR-T therapy is designed to recognize intracellular antigens in addition to extracellular antigens, which may increase the number of tumors that can be successfully targeted.
Cytovant will focus on development programs that have the potential to transform the treatment of diseases highly prevalent in Asian patients. Its therapeutic approaches includes but are not limited to T cell receptor-engineered T cell (TCR-T) therapy.